Universal Health Services’ AI Financial Impact, Surgical Volume Signals Clash in 2025 Earnings Call

Date of Call: Feb 26, 2026

Financials Results

• Revenue: For Q4 2025, revenue growth was 9% YOY. For full year 2025, revenue growth was 10% YOY.
• EPS: For Q4 2025, adjusted EPS increased 20% YOY. For full year 2025, adjusted EPS increased 31% YOY.
• Operating Margin: For Q4 2025, Same Facility segment EBITDA margin improved 50 basis points to 14.8%. For full year 2025, Same Facility segment EBITDA margin improved 150 basis points to 15.8%.

Guidance:

• Revenue for 2026 expected to be $18.4B to $18.8B, representing growth of 6% to 8%.
• Adjusted EBITDA net of NCI for 2026 expected to be $2.64B to $2.79B, representing growth of 2% to 8%.
• Adjusted net income attributable to UHS per diluted share for 2026 expected to be $22.64 to $24.52, representing growth of 4% to 13%.
• Same-facility volume growth expected to be 2% to 3% for both segments.
• Capital expenditures for 2026 expected to be $950M to $1.1B.

Business Commentary:

Strong Financial Performance:

• Universal Health Services reported a 9% increase in revenue for Q4 2025, with adjusted EBITDA net of NCI rising by 10% and adjusted EPS increasing by 20% compared to Q4 2024. For the full year, revenue growth was 10%, adjusted EBITDA net of NCI increased 15%, and adjusted EPS increased 31%.
• The strong performance was driven by effective expense management, sequential volume improvements in behavioral health, solid pricing across segments, and significant share repurchase activity.

Growth and Expansion Strategy:

• UHS added 2 new acute care hospitals and has plans for significant new capacity, including 3 inpatient expansions and a new 156-bed hospital in Florida, with more projects expected in 2026.
• The growth strategy is supported by a disciplined approach to new bed capacity and an intensified focus on outpatient services, including the opening of 10 new freestanding centers under the Wellness brand in 2025.

Operational and Technological Advancements:

• UHS improved acute care margins through reduced contract labor costs and strong supply chain management, with a 2% reduction in same-facility acute care length of stay.
• The company has deployed AI and advanced technologies, such as Agentic AI to improve post-discharge care and AI-based solutions to enhance revenue cycle operations, aiming to improve clinical outcomes and operating efficiency.

Challenges and Regulatory Impacts:

• UHS faces a 25% to 30% decline in exchange volumes in 2026, with an estimated $75 million adverse pretax earnings impact, and a $35 million headwind from new California staffing regulations.
• The decline in exchange volumes is due to reductions in health insurance exchanges, while the California regulations are expected to increase labor costs and disrupt census in the short term.

Sentiment Analysis:

Overall Tone: Positive

• The CEO stated, 'We closed out 2025 with strong results.' He also said, 'We are optimistic about the future because we continue to invest in our people, our facilities and in technology that will improve quality, patient experience and operating efficiency.' The company provided positive growth guidance for 2026.

Q&A:

• Question from Albert Rice (UBS): Regarding 2026 guidance, can you provide details on embedded pricing assumptions and any changes in managed care rates?
  Response: Acute care pricing expected 3-4%, in line with historical averages; Behavioral pricing expected 2-3%, moderating from prior strong levels but in line with historical rates.

• Question from Albert Rice (UBS): How do AI applications translate into financial impact on operating performance and over what timeframe?
  Response: AI drives efficiencies in revenue cycle and reduces readmissions; benefits are significant but difficult to precisely quantify, with a focus on administrative and operational improvements.

• Question from Ann Hynes (Mizuho Securities): Within acute care volume guidance, what is the split between surgical and medical volume? How did the Nevada market perform in 2025 and what is the 2026 outlook?
  Response: Surgical volume growth is expected to be somewhat similar to overall volumes. Nevada was slightly challenged in 2025 due to lower tourist volumes, but employment trends are stable and an uptick is assumed for 2026.

• Question from Anna (Wolfe Research): What are you seeing regarding exchange volumes and visibility on potential bad debt?
  Response: Guidance assumes a 25-30% decline in exchange volumes, with some underreporting initially; risk is increased but accounted for in assumptions, with more precision expected in coming months.

• Question from Andrew Mok (Barclays): Regarding the California staffing regulation headwind, why does the annual impact reduce to $30M after the first year?
  Response: The initial $35M headwind includes start-up costs and short-term volume disruption; ongoing costs are reduced after full staffing is achieved, leading to a lower annual impact of $30M.

• Question from Benjamin Hendrix (RBC Capital Markets): Where is demand for outpatient behavioral services, and what is the optimal long-term business mix between inpatient and outpatient?
  Response: Outpatient services represent ~10% of Behavioral revenue and are growing; demand is strong for step-in and step-down services. The strategy is to grow outpatient faster than inpatient, which has better margins.

• Question from Stephen Baxter (Wells Fargo): Regarding the California staffing regulation, could there be spillover impact on wage structure or potential reimbursement offsets?
  Response: Assumptions are based on direct staffing cost changes; wage inflation and recruitment incentives are considered, but no reimbursement offsets are forecasted, though efforts will be made to work with payers.

• Question from Jason Cassorla (Guggenheim): With behavioral volume accelerating and pricing moderating, would you expect organic margin expansion?
  Response: Yes, 4-6% revenue growth is expected to exceed operating cost increases, especially with outpatient margins being better and headcount investment moderating.

• Question from Jason Cassorla (Guggenheim): How can length of stay be improved through AI or technology?
  Response: Acuity-adjusted LOS is below pre-pandemic levels; main obstacle is subacute capacity availability, which is expected to improve, along with internal efficiency initiatives.

• Question from Matthew Gillmor (KeyBanc): What is the status of Medicaid supplemental program approvals in Florida and California, and visibility on rural health funding?
  Response: Florida program is expected to be approved with a $45-50M benefit. California program faces more hurdles and is not quantified. Rural program has potential but is not material.

• Question from Pito Chickering (Deutsche Bank): Is there a target leverage ratio, and why maintain low leverage unless large deals are anticipated?
  Response: Ideal leverage is 2x-3x; low leverage provides flexibility for opportunistic M&A without needing to lever up dramatically in absence of specific deals.

• Question from Pito Chickering (Deutsche Bank): Can you provide real examples of AI-driven efficiencies in cash collections and cost savings?
  Response: Examples include AI-driven post-discharge calls reducing staffing, and patient safety technology improving quality and potentially reducing malpractice costs; exact dollar savings are hard to pinpoint.

• Question from Craig Hettenbach (Morgan Stanley): With pricing normalizing, what is confidence in achieving steady behavioral volume growth?
  Response: Confidence is high due to sequential improvements in 2025, investments in staffing, and being near the 2-3% target, making it achievable in 2026.

• Question from Craig Hettenbach (Morgan Stanley): Are there any key highlights or areas for capital investment in 2026?
  Response: Key projects include a new de novo hospital in Florida, a tower in Florida, a replacement facility in California, and behavioral JV hospitals; focus remains on outpatient expansion and core acute inpatient capabilities.

• Question from Samuel Becker (Goldman Sachs): What is your overall assessment of healthcare policy risk, including Medicaid work requirements?
  Response: Impact of Medicaid work requirements in 2027 is difficult to quantify due to varying state specifics; no precise estimates from hospital companies currently.

• Question from Benjamin Rossi (JPMorgan): How are you thinking about cash flow from operations for 2026?
  Response: Historically, cash flow from operations is 75-80% of operating income less NCI; this is expected to be a safe measure for 2026 despite timing issues.

• Question from Benjamin Rossi (JPMorgan): How would you characterize supply dynamics and potential cost offsets in 2026?
  Response: Supply costs were well-controlled in 2025; no significant pressure points expected in 2026, with opportunities for efficiency via clinician preference management.

• Question from Hua Ha (Baird): How do you think about the durability of long-term behavioral pricing and potential shifts in Medicaid volume strategy?
  Response: DPP reimbursement will remain beneficial until 2028; outpatient growth with better commercial payer mix is a natural hedge for future Medicaid profitability declines.

• Question from Ryan Langston (TD Cowen): How does the 3.5-4% FTE growth in behavioral translate into the 2-3% volume growth outlook?
  Response: Headcount increases were targeted in markets where staffing was an obstacle to volume growth; filling these positions provides confidence in achieving the 2-3% patient day volume target.

Contradiction Point 1

Financial Impact and Timeline of AI Applications

Contradiction on quantifying AI's financial impact and the associated timeframe.

Albert Rice (UBS Investment Bank) - Albert Rice (UBS Investment Bank)

2025Q4: Quantifying the full financial impact is difficult, but opportunities are seen as significant. - Steve Filton(CFO)

What is embedded in pricing for both segments regarding 2026 guidance, and how do AI applications impact revenues or margins over time? - Joshua Raskin (Nephron Research)

2025Q3: The company intends to maximize DPP benefits while they last. - Steve Filton(CFO)

Contradiction Point 2

Characterization of Surgical Volume Trends

Contradiction on whether surgical volumes are improving or still struggling.

Ann Hynes (Mizuho Securities USA LLC) - Ann Hynes (Mizuho Securities USA LLC)

2025Q4: Surgical volumes in 2025 were positive but grew slightly slower than overall volumes. - Steve Filton(CFO)

Within acute care volume growth of 2–3%, what is the split between surgical and medical, and how did the Nevada market perform in 2025 with growth expectations for 2026? - Benjamin Hendrix (RBC Capital Markets)

2025Q3: Surgical volumes are returning to more normal levels, having anniversaried the COVID catch-up period. - Steve Filton(CFO)

Contradiction Point 3

Long-term Revenue Growth Model for Behavioral Health

Inconsistent guidance on the primary driver for long-term behavioral revenue growth.

What was the focus of Michael Ha's question from Baird during the earnings call? - Michael Ha (Baird)

2025Q4: Growth in outpatient services (with better margins and more commercial payer mix) will help hedge against future Medicaid profitability declines. - Steve Filton(CFO)

How do you view long-term pricing durability post-DPP tailwinds (starting 2028) and potential shifts in Medicaid volume strategy? - Craig Hettenbach (Morgan Stanley)

2025Q2: The long-term model remains 7% revenue growth (4%-5% price, 2.5%-3% volume). While pricing has been strong, volume growth has been elusive but showed improvement from Q1 to Q2. - Steve G. Filton(CFO)

Contradiction Point 4

The Financial Impact and Outlook for California Staffing Regulations

Contradictory statements on the magnitude and characterization of the financial burden from the staffing regulation.

Andrew Mok (Barclays Bank PLC) - Andrew Mok (Barclays Bank PLC)

2025Q4: The regulation requires a different mix of licensed staff (more RNs), not necessarily more headcount... Once fully staffed in 2026, the ongoing cost burden will be lower than the full-year impact in 2027 and beyond, hence the $30M run rate. - Steve Filton(CFO)

Why is the California staffing regulation headwind $35M for 2026 but annualizes to $30M? - Philip Chickering (Deutsche Bank)

2025Q2: The Medicaid revenue reductions don't begin materially until 2028, giving the company time to adapt. Potential strategies include shifting revenue sources (especially in Behavioral), cost-cutting, and exploring new DPP programs. - Steve G. Filton(CFO)

Contradiction Point 5

Behavioral Volume Growth Guidance

Volume growth target appears inconsistent between quarters.

Albert Rice (UBS Investment Bank) - Albert Rice (UBS Investment Bank)

2025Q4: For behavioral health, pricing is expected to be 2–3%, a moderation from recent years but in line with historical rates. - Steve Filton(CFO)

What is embedded in pricing for both segments in 2026 guidance? - Justin Lake (Wolfe Research)

2025Q1: Full-year guidance presumes behavioral patient day revenue growth of 2.5% to 3%. - Steve Filton(CFO)